Completed NA INTERVENTIONAL 2-arm NCT01799876

Use of Cell Therapy to Enhance Arthroscopic Knee Cartilage Surgery

Autologous Cell Therapy Enhancement of Microfracture Surgery

Sponsor: Fondren Orthopedic Group L.L.P.

Conditions Articular Cartilage Defect Grade III or IV of the Knee

Interventions Autologous Cell Standard microfracture arthroscopic surgery

Updated 8 times since 2017 Last updated: Jan 9, 2019 Started: Feb 28, 2013 Primary completion: Aug 31, 2016 Completion: Aug 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01799876, this NA trial focuses on Articular Cartilage Defect Grade III or IV of the Knee and remains completed. Sponsored by Fondren Orthopedic Group L.L.P., it has been updated 8 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Feb 2019 — Jan 2021 [monthly]

Completed NA

Status: Unknown Status → Completed
Sep 2018 — Feb 2019 [monthly]

Unknown Status NA

Status: Active Not Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting NA
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting NA
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting NA

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondren Orthopedic Group L.L.P.
InGeneron, Inc.

Data source: Fondren Orthopedic Group L.L.P.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States